These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36394195)

  • 21. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
    HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis.
    Hou H; Ba H; Jin X; Luo P; Zhang Y; Li J; Jin J
    Medicine (Baltimore); 2024 Jul; 103(27):e38558. PubMed ID: 38968505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
    Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
    Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
    Palacios R; Gómez-Ayerbe C; Casado JL; Tejerina F; Montes ML; Castaño M; Ocampo A; Rial D; Ribera E; Galindo MJ; Hidalgo C; Fariñas C; Montero M; Payeras T; Fanjul F; de la Torre J; Santos J
    HIV Med; 2023 Aug; 24(8):933-937. PubMed ID: 37016556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
    AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
    HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
    Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
    Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real world use of dolutegravir two drug regimens.
    Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
    AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
    Bosch B; Akpomiemie G; Chandiwana N; Sokhela S; Hill A; McCann K; Qavi A; Mirchandani M; Venter WDF
    Clin Infect Dis; 2023 Apr; 76(8):1492-1495. PubMed ID: 36519389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
    Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
    [No Abstract]   [Full Text] [Related]  

  • 35. Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
    Acosta RK; D'Antoni ML; Mulato A; Yant SR; Cihlar T; White KL
    Antimicrob Agents Chemother; 2022 May; 66(5):e0203821. PubMed ID: 35389236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
    Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
    PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
    Radford M; Parks DC; Ferrante S; Punekar Y
    AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
    Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
    Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
    Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
    Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.